Clearmind Medicine shares surge 10.14% after hours on positive CMND-100 trial data and DSMB safety approval.

Clearmind Medicine surged 10.14% in after-hours trading following the release of multiple press releases and analyses highlighting significant 2025 milestones. The company advanced its FDA-approved Phase I/IIa trial for CMND-100, a non-hallucinogenic MEAI-based therapy for Alcohol Use Disorder, including first-in-human dosing, completion of two cohorts with no serious adverse events, and unanimous DSMB approval to continue. Global trial sites at Yale, Johns Hopkins, and Israeli institutions validated its operational strength, while expanded international patent filings broadened its pipeline to obesity, depression, and metabolic disorders. The CEO emphasized the year’s pivotal role in transitioning Clearmind into a clinical-stage company, underscoring progress in safety, tolerability, and strategic IP growth as catalysts for future value.